WALTHAM, Mass., Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Thursday, September 5, 2024Location: New York, NY 2024 Cantor Fitzgerald Global Healthcare ConferenceDate: Tuesday, September 17, 2024Presentation Time: 3:40 p.m. E.T.Location: New York, NY Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Presentation Time: 11:30 a.m. E.T.Location: Virtual A webc

U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s

Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106 ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171 for mesothelin-expressing cancers, with the company expecting to initiate clinical development during 2024. QTTB: 9% | Q32 Bio shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $100 price target.

Guggenheim analyst Yatin Suneja initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $100.

Leerink Partners analyst Thomas Smith initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Outperform rating and announces Price Target of $54.